Novo Nordisk: STEP Young Wins, But Heart Trials Just Got Halted (Rating Downgrade) (NVO)

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

Key PointsNovo Nordisk was first to market with a GLP-1 weight-loss drug, but lost the lead to Eli Lilly.Novo Nordisk has been working hard to regain lost market share in the GLP-1 space.Using traditional valuation metrics, Novo Nordisk's stock looks cheap.10 stocks we like better than Novo Nordisk › GLP-1 weight-loss drugs burst onto the scene when Novo Nordisk (NYSE: NVO) introduced Wegovy to the world. There was so much demand that the drug m…

Novo Nordisk: STEP Young Wins, But Heart Trials Just Got Halted (Rating Downgrade) (NVO)

Novo Nordisk is downgraded to Hold as GLP-1 franchise strength is offset by pipeline setbacks and growth normalization. Click here to read more on NVO stock.